Showing posts with label drug classification. Show all posts
Showing posts with label drug classification. Show all posts

Sunday, 6 January 2013

When social drinking becomes a problem



Alcohol-related health issues among baby boomers are on the rise. Daily drinking can start off as a social event but turn into dependency, addiction experts say. So when does social drinking become alcoholism?
In the festive season, with office parties, Christmas, and new year, there is opportunity aplenty for yet another tipple.
Since the 1950s, alcohol consumption in the UK has gradually increased. The NHS now spends more on alcohol-related illness among baby boomers than any other age group, with £825m spent on 55 to 74-year-olds in 2010-11 compared to £64m on under-24s.
Estimates also suggest about nine per cent of men and three per cent of women in the UK show signs of alcohol dependence.
But it is the functioning alcoholic that can slip under the radar - before their health issues are severe enough to need treatment.
Stressed woman drinking alcohol
Straight vodka
Dr John Marsden, an alcohol and drug dependency expert from King's College London, says a typical functioning alcoholic can manage to hold down a job despite having a "very severe drinking problem that they have been incubating over a very long period".
"Alcohol problems are difficult to understand because they do not occur overnight. They are hidden from view which makes functioning alcoholics a group we cannot easily help."
Rob C, who is 61, was one of them. At his worst he was drinking 1.5 litres of straight vodka per day.
"Then I began to suffer blackouts, losing whole days and not remembering anything."
He would be first to arrive at work, which made him able to set out his "drinks for the day with what looked like a bottle of mineral water".
"I would hide bottles around the office. You think nobody else knows, that it doesn't smell, that you're getting away with it. But of course they did notice."
Life saver
For several years, maintaining a full-time finance job, he drank increasingly more during the day.

Start Quote

There was work, there was money and increasingly the motivation to alter ones mood quickly. Alcohol has been the drug of choice to do that”
Dr John MarsdenAddiction expert
What started as a social pastime nearly cost him his relationship. Now sober for eight years, looking back he says that even if a colleague had said something at the time, he would not have listened.
"I resented the changes at work and told myself I deserved a drink. I would buy wine at lunchtime and drink it from a polystyrene cup."
Wine turned to vodka for a "bigger kick" and lunchtime turned to morning through to night.
Early retirement on medical grounds made his addiction worse. It was only when his partner threatened to kick him out that he sought help with Alcoholics Anonymous, who he says saved his life.
Rob is not alone. In the last decade there has been a 63% increase in prescriptions for the treatment of alcohol dependency in England, as well as a 20% rise in deaths from liver disease.
Prof Sir Ian Gilmore, a liver specialist and chair of the Alcohol Health Alliance, believes the number of people dying from liver disease will keep rising.

A silent killer

Illustration of liver
The majority of people who have alcohol-related health problems are middle-aged, which Sir Ian says is a consequence of chronic alcohol misuse - many years of frequent heavy drinking, rather than binge drinking - a session of drinking large amounts of alcohol in a small space of time.
Illustration of liver
But he says that though there is a big overlap, it is important to remember not all heavy social drinkers are dependent on alcohol.
"Some people can control their drinking after work, others can't. If people are frequently drinking harmful levels of alcohol - over 50 units a week for men, 35 for women - most will end up suffering some form of physical, mental or social harm."
A lifetime's worth of drinking is catching up with baby boomers, says Emily Robinson from the Alcohol Concern.
The charity hopes that their campaign, Dry January, will help get people thinking about how much they drink, especially at home when units are harder to measure, and crucially, before they reach a stage where drinking is affecting their health.
"The issue of people drinking every day is worrying as it's a way of slipping into dependency, as you need to drink a little more each time to feel the same effects," she says.
Dr Marsden suggests the line between social drinking and dependency is clear. He says the first question that needs to be asked by clinicians or family members is: "Has anyone expressed concern to you about your drinking?"

What's a unit?

  • Half a pint of standard strength (4%) beer, cider or lager
  • A single pub measure of spirit (25ml)
  • Half a standard glass of wine (175ml)
This question assesses whether a person's behavior has negatively impacted on someone close to them, he adds.
"If your alcohol consumption has caused a problem for someone else - I'm not rushing to label you an alcoholic but suggesting you need to take a closer look at your behaviour."
There is a clear reason the baby boomer generation is now most at risk from alcohol-related problems, argues Dr Marsden.
A hard-working generation led to an appetite for entertainment and relaxation.
"There was work, there was money and increasingly the motivation to alter one's mood quickly. Alcohol has been the drug of choice to do that."
For more information on Drug and Alcohol Testing visit Drug Test Australia or call 1300 660 636 or send an email inquiry to sales@drugtestaustralia.com.au


Thursday, 13 December 2012

Kiwi Kronic 'king' facing drug charges in Australia



New Zealand's "king" of legal cannabis faces trafficking charges in Australia after allegedly being found with a "commercial quantity" of drugs.
Matthew Wielenga was arrested about 8pm on Friday in the Melbourne suburb of Southbank. The 30-year-old is facing charges of trafficking a commercial quantity of synthetic cannabinoids and two counts of possessing a drug of dependence.
The Melbourne Magistrates Court yesterday heard he was found with more than 100kg of Kronic, a synthetic marijuana product, and 1kg of white powder said to be a synthetic cocaine sold as Diablo.
The alleged drugs are yet to be analysed and Wielenga had made no admissions, the court heard.
Defence lawyer Greg Barns said the elements of Kronic kept changing and might not fall within the substances banned by Victorian law.
Wielenga was granted bail on a A$100,000 surety and is to reappear in court on March 18.
Dressed in jeans and a dark T-shirt, he appeared to be listening intently throughout the court hearing.
The New Zealander must stay at an address in the suburb of Richmond, report to local police daily and surrender his passport.
Wielenga is a director of Lightyears Ahead, the company responsible for bringing Kronic to New Zealand. Kronic is laced with chemicals mimicking cannabis and is often much stronger than the real thing. It was banned in New Zealand in August.
Wielenga, who ran his lucrative Kronic empire from Albany on Auckland's North Shore, is understood to have travelled to Australia with about nine of his employees last week. The group were in Australia for a music festival, a source said.
Nisha Din, described as the general manager of Lightyears Ahead, said the firm strongly denied any illegal activity.
She referred the Herald to Wellington law firm Chen Palmer.
Partner Mai Chen did not return calls last night.
Wielenga describes his party pill business on his Facebook page: "I run my own company that provides products to get people high. They are sold all over the world, which gives me a great excuse to travel."
Anna Leask, NZ Herald

Monday, 10 December 2012

Kronic Test: Available from Drug Test Australia

Drug Test Australia now stocks testing kits for Synthetic Marijuana (Kronic).

This drug is widely used now in Australia by employees from all industries and sectors, with reports of growing popularity in the mining and fabrication sectors.

Employees use this drug in place of marijuana because it is widely believed to be 'non-detectable' in drug tests. Urine or Saliva.

This was true, until now.

Introducing the K2 Spice Test, a single dip cassette test, for use in urine testing that will detect synthetic Cannabinoids in human urine. These tests can be used on their own, or in conjunction with conventional urine test to effectively screen your workforce!

For more information, please contact us;
Website: www.drugtestaustralia.com.au
Phone: 1300 660 636
Email: sales@drugtestaustralia.com.au

K2-Spice dip test image

Thursday, 15 November 2012

Designer drug called 'Smiles' linked to teen deaths


Posted by Drug Test Australia

By Stephanie Pappas
Published September 24, 2012
LiveScience




Several teenagers’ deaths have law enforcement officials concerned about the next in a long line of illegal synthetic drugs: 2C-I, also known as "Smiles."

The drug, a hallucinogen, has been linked to two deaths in East Grand Forks, North Dakota, though little is known about this drug's dangers. Other synthetic drugs, including K2 or "fake weed," have caused problems by proliferating before being made illegal. 

"There is hardly any research at all in the scientific literature on these things, even in animals, much less any sort of formal safety evaluation in humans," said Matthew Johnson, a professor of behavioral pharmacology at Johns Hopkins University.

A new high

2C-I is part of the 2C family of drugs, a group of closely related molecules that have psychedelic effects. Along with the other 2Cs, 2C-I was discovered by chemist and synthetic-drug guru Alexander Shulgin, who published the formulas of psychoactive drugs in his book "PiHKAL: A Chemical Love Story." As of July 2012, the Drug Enforcement Administration classifies 2C-I as a Schedule I controlled substance, making it illegal to manufacture, buy, sell or possess the drug.

Usually sold in powder form, 2C-I can also be taken as a tablet. Users often mix the powder form with a stabilizing substance, such as chocolate or candy, before ingesting. The drug’s effects include auditory and visual hallucinations, along with feelings of giddiness, relaxation and empathy.

"[M]y conversations were extremely clear and insightful,” wrote one 2C-I user on erowid.org, which hosts an online version of Shulgin's book. “The degree of honesty was incredible."

But the drug has nasty side effects, too, as the case of the East Grand Forks teenagers attests. According to news reports, a 17-year-old went to a McDonald's in June after taking 2C-I mixed with melted chocolate given to him by an 18-year-old friend. The younger teenager began hyperventilating and hitting his head against the ground. His friends took him home, but several hours later, he stopped breathing. His 18-year-old companion has been charged with third-degree murder and second-degree manslaughter.

The night before, an 18-year-old was found dead in the same town, reportedly of a similar overdose, prompting police to warn about a tainted batch of 2C-I.

"2C-I is related to a class of drugs called phenylethylamines, which in turn are related to amphetamines," said Rudy Richardson, a toxicologist at the University of Michigan. Amphetamines (best known in the illegal drug market from methamphetamine) increase heart rate and can cause the heart to beat out of rhythm, Richardson told LiveScience. Those heart arrhythmias, in turn, can be fatal. 

More commonly occurring unpleasant side effects of 2C-I include nausea and vomiting, according to online, anecdotal reports. Some users experience "bad trips," which can include terrifying hallucinations and feelings of fear and panic.

Not your average hallucinogen

2C-I's hallucinogenic effects may fool some users into thinking it is difficult to overdose on the drug, Johnson told LiveScience. Classic hallucinogens, such as LSD and psilocybin, or "magic mushrooms," are unusual in that they don't typically cause immediate bodily harm, he said — though they can be dangerous to people with psychotic tendencies and those who walk into traffic or off of buildings while under the influence, he added.

Like LSD and psilocybin, 2C drugs cause hallucinogens by interfering with the brain's serotonin system, Johnson said. But drugs in the 2C class differ in having stimulant effects. That means that 2C drugs can kill in the same ways as meth and other uppers, including by causing strokes, he said.

Adding to the danger, users may not always know what they're getting. In 2009, for example, two people died in the U.S. and in Denmark after taking what they believed to be a 2C drug called 2C-B-fly. Instead, it was likely a similar, but much stronger drug called bromo-dragonfly.

"Until they're tested, you really don't know what you're buying," DEA spokesperson Michael Rothermund told LiveScience.

There are no national statistics on 2C-I use, Rothermund said, and it's not clear how widespread the drug really is. But Johnson warned that synthetic drugs should be considered seriously.

"I just want to caution people to be careful and not assume all drugs are the same — even if they have similar effects," he said.

Read more at Fox News; http://www.foxnews.com/health/2012/09/24/latest-designer-drug-called-miles-linked-to-teen-deaths/#ixzz2CL62SJMI

Contact us at Drug Test Australia
Website; www.drugtestaustralia.com.au
Email; Sales@drugtestaustralia.com.au
Phone; 1300 660 636

Altering the Mind; Hallucinogens You Haven't Heard Of

Posted by Drug Test Australia
Original; http://www.livescience.com/16286-hallucinogens-lsd-mushrooms-ecstasy-history.html

Ayahuasca

Ayahuasca is a hallucinatory mixture of Amazonian infusions centred around the Banisteriopsis caapi vine. The brew has long been used by native South American tribes for spiritual rituals and healing, and like other hallucinogens, ayahuasca often triggers very intense emotional experiences (vomiting is also common). In 2006, National Geographic writer Kira Salak described her experience with ayahuasca in Peru for the magazine.

"I will never forget what it was like. The overwhelming misery. The certainty of never-ending suffering. No one to help you, no way to escape. Everywhere I looked: darkness so thick that the idea of light seemed inconceivable," Salak wrote. "Suddenly, I swirled down a tunnel of fire, wailing figures calling out to me in agony, begging me to save them. Others tried to terrorize me. 'You will never leave here,' they said. 'Never, Never.'

Nonetheless, Salak wrote, when she broke free of her hallucinations, her crippling depression was alleviated. Its anecdotal experiences like this that have led researchers to investigate the uses of hallucinogens as therapy for mental disorders such as anxiety, depression and post-traumatic stress disorder.

Ayahuasca, made from the vine Banisteriopsis caapi

Peyote

Peyote is a cactus that gets its hallucinatory power from mescaline. Like most hallucinogens, mescaline binds to serotonin receptors in the brain, producing heightened sensations and kaleidoscopic visions.

Native groups in Mexico have used peyote in ceremonies for thousands of years, and other mescaline-producing cacti have long been used by South American tribes for their rituals.

Peyote has been the subject of many a court battle because of its role in religious practice; currently, Arizona, Colorado, New Mexico, Nevada and Oregon allow some peyote possession, but only if linked to religious ceremonies, according to Arizona's Peyote Way Church of God.

Peyote Cactus

'Magic' Mushrooms

The "magic" ingredient in hallucinogenic mushrooms is psilocybin, a compound that breaks down into psilocin in the body. Psilocin bonds to serotonin receptors all over the brain, and can cause hallucinations as well as synesthesia, or the mixture of two senses. Under the influence, for example, a person might feel that they can smell colours.

People have been ingesting psilocybin-continuing mushrooms for thousands of years. Synthetic psilocybin is now under study as a potential treatment for anxiety, depression and addiction.

'Magic' Mushroom, containing Psilocybin
PCP

Best known by its street name, "angel dust," PCP stands for phencyclidine. The drug blocks receptors in the brain for the neurotransmitter glutamate. It's more dangerous than other hallucinogens, with schizophrenia-like symptoms and nasty side effects.

Those side effects are why PCP has no medical uses. The drug was tested as an anaesthetic in the 1950s and used briefly to knock out animals during veterinary surgeries.

But by the 1960s, PCP had hit the streets and was being used as a recreation drug, famous for the feelings of euphoria and invincibility it bestowed on the user. Unfortunately, a side effect of all that euphoria is sometimes truly destructive behaviour, including users trying to jump out of windows or otherwise self-mutilating. Not to mention that high enough doses can cause convulsions.

PCP

Ibogaine

Derived from the African iboga plant, ibogaine is another hallucinogen with a long history of tribal use. More recently, the drug has shown promise in treating addiction, although mostly in Mexico and Europe where ibogaine treatment is not prohibited as it is in the U.S.

Using ibogaine as therapy is tricky, however. The drug can cause heart rhythm problems, and vomiting is a common side effect. The Massachusetts-based Multidisciplinary Association for Psychedelic Research (MAPS) reports that an estimated 1 in 300 ibogaine users die due to the drug.

The group is studying the long-term effects of ibogaine on patients in drug treatment programs in New Zealand and Mexico.

Ibogaine

Salvia divinorum
Salvia divinorum, also known as seer's or diviner's sage, grows in the cloud forest of Oaxaca, Mexico. The native Mazatec people have long used tea made out of the leaves in spiritual ceremonies, but the plant can also be smoked or chewed for its hallucinogenic effects.

Salvia is not currently a controlled substance, according to the National Institute on Drug Abuse, but it is under consideration to be made illegal and placed in the same drug class as marijuana.

Salvia divinorum
MDMA

Ecstasy, "E" or "X" are the street names for MDMA, or (get ready for a long one) 3,4-methylenedioxymethamphetamine. The drug acts on serotonin in the brain, causing feelings of euphoria, energy and distortions of perception. It can also nudge body temperatures up, raising the risk of heat stroke. Animal studies suggest that MDMA causes long-term and potentially dangerous changes in the brain, according to the National Institute on Drug Abuse.

MDMA was first synthesized by a chemist looking for substances to stop bleeding in 1912. No one paid the compound much mind for the next half-decade, but by the 1970s, MDMA had hit the streets. It was popular at raves and nightclubs and among those who liked their music psychedelic. Today, ecstasy is still a common street drug, but researchers are investigating whether MDMA could be used to treat post-traumatic stress disorder and cancer-related anxiety.

MDMA

Contact us at Drug Test Australia
Website; www.drugtestaustralia.com.au
Email; Sales@drugtestaustralia.com.au
Phone; 1300 660 636

Tuesday, 13 November 2012

New types of Synthetic Cannabis; Report

A new type of Synthetic Cannabis called 'Venom' was seized last week in Perth by West Australian Police. Typically, Synthetic Cannabinoids (marketed as 'legal highs', 'incense' or 'herbal highs') contain one or more compounds that mimic some effects of cannabis.

This report looks at this phenomenon in Australia, and attempts to offer information to provide a deeper understanding of the issues at play, and the trends that we are seeing in the local community and internationally.

Originally developed through research and then named for its developer John W. Huffman (JWH numbered compounds), the most common of which is named JWH-018. John Huffman professor emeritus of organic chemistry at Clemson University, beginning in 1984, developed many cannabinoid compounds to aid in medical research. It was not his wish that they be used for recreational purposes. HU-210 first synthesized in at Hebrew University in 1988 is purportedly up to 800 times the strength of natural THC from cannabis, a potent analgesic, it is one of the 8 other variants developed at this time. CP 47,497 developed by Pfizer in the 1980’s is another cannabinoid compound, developed for research. North-eastern University also synthesised cannabinoid compounds, listed as AM, such as AM-2201.

In later years, starting in Germany in 2003, these compounds began to be sold as marijuana alternatives. The laws in Australia vary from state to state, with some such as WA having a harsher standpoint.



They can currently in NSW be purchased from Tobacconists, Adult Stores and Online Retailers (in small or large quantities) among others. They are sold as herbal incense, and often come with a disclaimer, Warning; Not for human consumption.

Typically the synthetic compound is sold online in powder form, it is then combined with other ingredient  including organic materials to make a 'blend' of plant material/inert herbs, that is sold retail and wholesale both legally and illegally, that can be smoked by users, much like Marijuana.


In recent years, the laws have changed state to state, and online retailers will only send certain brands contain non-listed chemicals, to certain areas. A way of circumventing this law is through changing of the active ingredients.

JWH-018 and JWH-073 are some of the more common compounds used in these products to date.

New synthesized blends of this product, including the drugs seized in Perth, contained these two compounds, AM-2201 and XLR-11. XLR-11 is now banned under New Zealand law. 
THC (Marijuana) and Synthetic cannabis compounds designed to mimic its effects
Several types of synthetic compounds available online.
These chemical compounds can be bought on the Internet from companies claiming to reside in the US and elsewhere, and are sold as 'research chemicals'. They are then combined with organic materials and distributed under different brand names, by wholesalers and retailers nationally.

The part which makes it difficult to police, legislate and difficult to screen in workplace situations, is that these companies have a vested interest in keeping their products ‘legal’ and ahead of state and federal legislation. This means none of these products are very static, having to be regularly rebranded, and the ingredients slightly changed to keep up with legislation changes.

The effect has been that some brands of synthetic marijuana are being redeveloped with synthetic compounds that are not yet classified, or have not been seen before. For example AB-001, is a designer drug, we have no information on who developed it, but that was discovered to be used in synthetic smoking blends in Europe in 2010-2011.

In truth, these types of substances are available online to anyone that wants to purchase them, and will be sent to by post to anywhere that they are willing to be sent to, including major cities, small towns and remote mining locations, anywhere. Typical THC drug tests (urine or saliva) will NOT pick up these substances, though currently urine tests (such as K2 Spice) are available in Australia that are designed to screen for a range of these compounds.

Any person involved in Drug testing or drug education should keep up with the latest developments in drugs of abuse in the community. Only through informed discussion can gain a better, unbiased view of the current situation, and put in place measures to deal with these issues.

If you would like more information on this subject, please contact us at www.drugtestaustralia.com.au or email sales@drugtestaustralia.com.au or Phone 1300 660 636



Thursday, 1 November 2012

Methamphetamine Vaccine Shows Promising Results in Early Tests


Posted by; Drug Test Australia
Article from HealthCanal.com 01/11/2012 20:51:00




 

Blocking a meth high could help addicts committed to recovery
LA JOLLA, CA  – Scientists at The Scripps Research Institute (TSRI) have performed successful tests of an experimental methamphetamine vaccine on rats. Vaccinated animals that received the drug were largely protected from typical signs of meth intoxication. If the vaccine proves effective in humans too, it could become the first specific treatment for meth addiction, which is estimated to affect 25 million people worldwide.
“This is an early-stage study, but its results are comparable to those for other drug vaccines that have then gone to clinical trials,” said Michael A. Taffe, an associate professor in TSRI’s addiction science group, known as the Committee on the Neurobiology of Addictive Disorders. Taffe is the senior author of the study, which is currently in press with the journal Biological Psychiatry.
A Common and Dangerous Drug of Abuse
Over the past two decades, methamphetamine has become one of the most common drugs of abuse around the world. In the United States alone there are said to be more than 400,000 current users, and in some states, including California, meth accounts for more primary drug abuse treatment admissions than any other drug. Meth has characteristics that make it more addictive than other common drugs of abuse, and partly for this reason, there are no approved treatments for meth addiction.
In recent years, scientists at TSRI and other institutions have taken the innovative approach of developing vaccines against addictive drugs. These vaccines evoke antibody responses against drug molecules, just as traditional vaccines evoke antibody responses against viruses or bacteria. Anti-drug antibodies are meant to grab hold of drug molecules and keep them from getting into the brain—preventing the drug from giving the user a high and removing the incentive for taking the drug.
Vaccines against nicotine and cocaine are already in clinical trials. Some meth vaccines have been tested in animals, but generally with unpromising results. The methamphetamine molecule is structurally simple, making it relatively unnoticeable to the immune system. Meth and its main metabolite, ordinary amphetamine, also tend to linger once they get into the nervous system, so that even a little drug goes a long way. “The simple structure and long half-life of this drug make it a particularly difficult vaccine target,” said Kim Janda, the Ely R. Callaway, Jr. Professor of Chemistry and member of the Skaggs Institute for Chemical Biology at TSRI.
‘Encouraging Results’
Two years ago Janda and his laboratory developed six candidate meth vaccines. In each, the main active ingredient was a chemical cognate of the methamphetamine molecule—that otherwise would be too small to evoke any antibody response—linked to a larger, antibody-provoking carrier molecule. Early tests in mice indicated that three of these vaccine candidates could evoke a strong antibody response to meth. Taffe’s laboratory later tested these three vaccines in rats and found the one, designated MH6, that worked best at blocking two typical effects of meth—an increase in physical activity and a loss of the usual ability to regulate body temperature.
In the new study, members of Taffe’s laboratory, including Research Associate Michelle L. Miller, who was lead author of the study, investigated the MH6 vaccine in more depth. Using a different experimental setup, they found again that it prevented a rise in body temperature and burst of wheel-running hyperactivity that otherwise occur after meth exposure. Underlying these promising effects on behavioral measures was a robust antibody response, which in vaccinated rats kept more of the drug in the bloodstream and out of the nervous system, compared to control rats. “These are encouraging results that we’d like to follow up with further animal tests, and, we hope, with clinical tests in humans some day,” said Miller.
“I think that this vaccine has all the right features to allow it to move forward in development,” said Janda. “It certainly works better than the other active vaccines for meth that have been reported so far.”

The Next Big Challenge
separate group of researchers has reported promising animal test results for an antibody-based treatment. In this approach, the anti-meth antibodies are grown in cultured cells using standard biotechnology methods and then injected into the animal in a concentrated dose, preventing a meth high. Antibody-based therapies are commonly used to treat cancer and chronic immunologicalconditions. But they are typically expensive, costing thousands of dollars per dose, and the effects of a dose last for a few weeks at most. A meth treatment probably would have to be much more cost-effective to be widely useful, as addicts frequently have little money and no health insurance and receive their treatments from government health services.
In principle, an active vaccine would be cheap to make and administer and would confer protection for months per dose, rather than weeks with conventional monoclonal antibody therapy. In practice, active meth vaccine candidates don’t yet last that long; for example, the MH6 candidate in the current study was given in four doses over 12 weeks. But Janda and Taffe believe that with further adjustment, an active meth vaccine could sustain an anti-meth antibody response for a much longer period.
“Extending the duration of protection is the next big scientific challenge in this field,” said Taffe.
In addition to Taffe, Janda and Miller, other co-authors of the report, “A Methamphetamine Vaccine Attenuates Methamphetamine-Induced Disruptions in Thermoregulation and Activity in Rats,” were Amira Y. Moreno, from TSRI’s Department of Chemistry; and Shawn M. Aarde, Kevin M. Creehan, Sophia A. Vandewater, Brittani D. Vaillancourt and M. Jerry Wright Jr., from TSRI’s Committee on the Neurobiology of Addictive Disorders. For more information on the paper, seehttp://www.biologicalpsychiatryjournal.com/article/S0006-3223(12)00803-7/abstract.
The study was funded in part by a National Institute on Drug Abuse grant (#DA024705).

About The Scripps Research Institute
The Scripps Research Institute is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. Over the past decades, Scripps Research has developed a lengthy track record of major contributions to science and health, including laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. The institute employs about 3,000 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including three Nobel laureates—work toward their next discoveries. The institute's graduate program, which awards Ph.D. degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
# # #
For information:
Office of Communications
Tel: 858-784-8134
Fax: 858-784-8136
http://www.healthcanal.com/medical-breakthroughs/33522-Meth-Vaccine-Shows-Promising-Results-Early-Tests.html

Contact us at Drug Test Australia
Website; www.drugtestaustralia.com.au
Email; Sales@drugtestaustralia.com.au
Phone; 1300 660 636